GeneDx (NASDAQ:WGS) Director Casdin Capital, Llc Acquires 140,000 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) Director Casdin Capital, Llc bought 140,000 shares of GeneDx stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average price of $43.81 per share, with a total value of $6,133,400.00. Following the purchase, the director owned 3,507,164 shares of the company’s stock, valued at $153,648,854.84. This trade represents a 4.16% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Casdin Capital, Llc also recently made the following trade(s):

• On Tuesday, May 19th, Casdin Capital, Llc acquired 185,000 shares of GeneDx stock. The shares were bought at an average cost of $42.60 per share, with a total value of $7,881,000.00.
• On Monday, May 18th, Casdin Capital, Llc acquired 175,000 shares of GeneDx stock. The stock was bought at an average price of $42.55 per share, with a total value of $7,446,250.00.

GeneDx Stock Performance

WGS stock opened at $44.73 on Thursday. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95. The company has a 50 day moving average price of $61.30 and a 200 day moving average price of $99.89. GeneDx Holdings Corp. has a fifty-two week low of $32.21 and a fifty-two week high of $170.87. The stock has a market capitalization of $1.33 billion, a PE ratio of -16.69 and a beta of 2.06.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.22). GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.The company had revenue of $102.25 million during the quarter, compared to the consensus estimate of $112.46 million. During the same quarter last year, the firm earned ($0.23) EPS. Analysts forecast that GeneDx Holdings Corp. will post -1 EPS for the current year.

Institutional Investors Weigh In On GeneDx

Several institutional investors and hedge funds have recently added to or reduced their stakes in WGS. Bank of America Corp DE raised its holdings in shares of GeneDx by 77.5% in the 1st quarter. Bank of America Corp DE now owns 234,606 shares of the company’s stock valued at $15,066,000 after purchasing an additional 102,456 shares during the period. California State Teachers Retirement System grew its stake in GeneDx by 31.2% in the 1st quarter. California State Teachers Retirement System now owns 25,045 shares of the company’s stock valued at $1,608,000 after buying an additional 5,951 shares during the last quarter. Ashford Capital Management Inc. grew its stake in GeneDx by 31.9% in the 1st quarter. Ashford Capital Management Inc. now owns 174,512 shares of the company’s stock valued at $11,207,000 after buying an additional 42,186 shares during the last quarter. Quantinno Capital Management LP grew its stake in GeneDx by 99.2% in the 1st quarter. Quantinno Capital Management LP now owns 3,810 shares of the company’s stock valued at $245,000 after buying an additional 1,897 shares during the last quarter. Finally, First Light Asset Management LLC acquired a new position in GeneDx in the 1st quarter valued at about $15,601,000. 61.72% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have commented on WGS shares. Jefferies Financial Group set a $150.00 target price on shares of GeneDx in a report on Monday, February 23rd. Weiss Ratings raised shares of GeneDx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 15th. Piper Sandler reaffirmed an “overweight” rating and issued a $130.00 target price (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th. Guggenheim reduced their target price on shares of GeneDx from $100.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Finally, Wall Street Zen lowered shares of GeneDx from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $96.43.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.